UK Autumn Statement 'delivers for science and innovation', ABPI says

23 November 2016

Trade group the Association of the British Pharmaceutical Industry (ABPI) has welcomed the impact of the UK Chancellor’s Autumn Statement on the sector.

As revealed by Prime Minister Theresa May on Monday, the UK government will provide an additional £2 billion ($2.49 billion) investment per year for research and development (R&D) by the end of this Parliament.

"Thlikely s focus on future innovation could not be more timely and is a clear signal to companies worldwide that the UK is open for business"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK